Vincerx Pharma, Inc. financial data

Symbol
VINC on Nasdaq
Industry
Pharmaceutical Preparations
Location
260 Sheridan Avenue, Suite 400, Palo Alto, CA
Fiscal year end
December 31
Former names
Vincera Pharma, Inc. (to 1/5/2021), LifeSci Acquisition Corp. (to 12/22/2020)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 194 % -52.4%
Debt-to-equity 87.1 % +130%
Return On Equity -308 % -102%
Return On Assets -164 % -48.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.6M shares +56.9%
Common Stock, Shares, Outstanding 31.4M shares +46.8%
Entity Public Float 23M USD +16.2%
Common Stock, Value, Issued 3K USD +50%
Weighted Average Number of Shares Outstanding, Basic 45.7K shares +114%
Weighted Average Number of Shares Outstanding, Diluted 45.7K shares +114%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 12.2M USD -22.5%
Operating Income (Loss) -28.2M USD +43.8%
Nonoperating Income (Expense) 1.14M USD -68.8%
Net Income (Loss) Attributable to Parent -27M USD +41.8%
Earnings Per Share, Basic -1.04 USD/shares +52.3%
Earnings Per Share, Diluted -1.04 USD/shares +52.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 2.94M USD -80.5%
Marketable Securities, Current 7.14M USD +24.8%
Cash, Cash Equivalents, and Short-term Investments 20.8M USD
Other Assets, Current 231K USD -59.5%
Assets, Current 11.7M USD -48.5%
Property, Plant and Equipment, Net 85K USD -38%
Operating Lease, Right-of-Use Asset 1.43M USD -41.5%
Other Assets, Noncurrent 173K USD -80.2%
Assets 14.9M USD -43.1%
Accounts Payable, Current 1.96M USD -35.9%
Accrued Liabilities, Current 1.72M USD -61.9%
Liabilities, Current 5.42M USD -38.7%
Operating Lease, Liability, Noncurrent 365K USD -77.7%
Other Liabilities, Noncurrent 50K USD 0%
Liabilities 5.84M USD -44.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 104K USD +100%
Retained Earnings (Accumulated Deficit) -181M USD -15.7%
Stockholders' Equity Attributable to Parent 9.11M USD -42.1%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 2.5B USD
Liabilities and Equity 14.9M USD -43.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.74M USD +40.9%
Net Cash Provided by (Used in) Financing Activities 5K USD +66.7%
Net Cash Provided by (Used in) Investing Activities 0 USD -100%
Common Stock, Shares Authorized 120M shares 0%
Common Stock, Shares, Issued 31.4M shares +46.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -7.66M USD -6.8%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3.03M USD -80%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD
Deferred Tax Assets, Valuation Allowance 37.7M USD +33.1%
Deferred Tax Assets, Gross 38.3M USD +32%
Operating Lease, Liability 1.64M USD -40.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -27M USD +41.8%
Lessee, Operating Lease, Liability, to be Paid 3.04M USD
Property, Plant and Equipment, Gross 256K USD 0%
Operating Lease, Liability, Current 1.27M USD +13.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.37M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.32M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 90K USD -66.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 28K USD
Deferred Tax Assets, Operating Loss Carryforwards 15.5M USD +60.5%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 30M shares 0%
Unrecognized Tax Benefits 1.24M USD +26.5%
Operating Lease, Payments 1.31M USD +4.06%
Additional Paid in Capital 190M USD +10.4%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 13K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 3.32M USD +47.4%
Interest Expense 8K USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%